Edgewise Therapeutics (EWTX) Operating Leases (2022 - 2026)

Edgewise Therapeutics (EWTX) has 5 years of Operating Leases data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 21.96% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 21.96% YoY), and the FY2025 full-year result was $3.0 million, down 20.45% from the prior year.
• Operating Leases slipped to $2.8 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $4.8 million in Q1 2023 to a low of $1.6 million in Q2 2022.
• A 5-year average of $3.5 million and a median of $3.6 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 191.56% in 2023 and declined 25.03% in 2024, its largest moves.
• Tracing EWTX's Operating Leases over 5 years: stood at $3.8 million in 2022, then increased by 16.68% to $4.4 million in 2023, then declined by 15.63% to $3.7 million in 2024, then decreased by 20.45% to $3.0 million in 2025, then decreased by 6.72% to $2.8 million in 2026.
• Business Quant data shows EWTX's Operating Leases at $2.8 million in Q1 2026, $3.0 million in Q4 2025, and $3.2 million in Q3 2025.